Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions.

Cancers (Basel) · 2023 · PMC10417818 · PMID 37568617

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

4.9 months (HR 0.44, CI 0.2–0.99) and there was a numerical OS advantage to ipatasertib, although this did not reach statistical significance in either the ITT or the pathway altered populations [ 40 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.